Search results
Results from the Tech24 Deals Content Network
Orlistat, sold under the brand name Xenical among others, is a medication used to treat obesity. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
e. Orlistat (Xenical), the most commonly used medication to treat obesity and sibutramine (Meridia), a medication that was withdrawn due to cardiovascular side effects. Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of ...
Sibutramine is a serotonin–norepinephrine reuptake inhibitor (SNRI) that, in humans, reduces the reuptake of norepinephrine (by ~73%), serotonin (by ~54%), and dopamine (by ~16%), [ 22] thereby increasing the levels of these substances in synaptic clefts and helping enhance satiety; the serotonergic action, in particular, is thought to ...
Pfizer announced on Dec. 1 that it was discontinuing phase 3 clinical trials of the twice-daily version due to high rates of adverse side effects. While these were mostly mild, a large percentage ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Weight loss in those receiving the fen-phen combination was significantly greater (8.4±1.1 kg) than in those receiving placebo (4.4±0.9 kg) and equivalent to that of those receiving fenfluramine (7.5±1.2 kg) or phentermine alone (10.0±1.2 kg). This amounts to an additional weight loss of 4±2 kg over the course of 24 weeks.
Her weight loss pictures are being used in online ads for a diet pill she's never used. She may not be able to legally get the company to stop using Woman claims her photo was stolen, used to sell ...
In clinical trials, tirzepatide has demonstrated some truly incredible numbers. Last year, Eli Lilly reported that in an 84-week study, patients were able to lose up to 26.6% of their body weight ...